- Home
- MEIP vs AMS Comparison
MEIP vs AMS Comparison
Compare MEIP & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- AMS
- Stock Information
- Founded
- MEIP 2000
- AMS 1980
- Country
- MEIP United States
- AMS United States
- Employees
- MEIP N/A
- AMS N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- AMS Medical Specialities
- Sector
- MEIP Health Care
- AMS Health Care
- Exchange
- MEIP Nasdaq
- AMS Nasdaq
- Market Cap
- MEIP 20.9M
- AMS 19.1M
- IPO Year
- MEIP 2003
- AMS N/A
- Fundamental
- Price
- MEIP $3.10
- AMS $3.06
- Analyst Decision
- MEIP Hold
- AMS
- Analyst Count
- MEIP 2
- AMS 0
- Target Price
- MEIP $7.00
- AMS N/A
- AVG Volume (30 Days)
- MEIP 13.5K
- AMS 365.3K
- Earning Date
- MEIP 09-24-2024
- AMS 08-14-2024
- Dividend Yield
- MEIP N/A
- AMS N/A
- EPS Growth
- MEIP N/A
- AMS 566.31
- EPS
- MEIP 3.93
- AMS 0.66
- Revenue
- MEIP $66,754,000.00
- AMS $23,104,000.00
- Revenue This Year
- MEIP $36.44
- AMS $25.13
- Revenue Next Year
- MEIP N/A
- AMS $20.18
- P/E Ratio
- MEIP $0.79
- AMS $4.62
- Revenue Growth
- MEIP 13.58
- AMS 13.49
- 52 Week Low
- MEIP $2.73
- AMS $2.16
- 52 Week High
- MEIP $7.87
- AMS $4.60
- Technical
- Relative Strength Index (RSI)
- MEIP 45.60
- AMS 48.41
- Support Level
- MEIP $3.06
- AMS $2.99
- Resistance Level
- MEIP $3.33
- AMS $3.19
- Average True Range (ATR)
- MEIP 0.14
- AMS 0.23
- MACD
- MEIP -0.01
- AMS 0.00
- Stochastic Oscillator
- MEIP 23.33
- AMS 14.44
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.